Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Hormone or other secreted growth regulatory factor,...
Reexamination Certificate
2011-04-05
2011-04-05
Gussow, Anne M. (Department: 1643)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Hormone or other secreted growth regulatory factor,...
C424S184100
Reexamination Certificate
active
07919103
ABSTRACT:
The invention relates to novel regulators of plasminogen activation and their use for regulating cell migration, plasminolysis, angiogenesis, fibrinolysis, for treating cancer and thrombo-embolic diseases such as heart stroke. Furthermore, the present invention relates to novel pharmaceutical compositions form regulating cell migration, plasminolysis, angiogenesis and for treating cancer. In particular, the present invention relates to a method of regulating the activation of plasminogen comprising contacting a solution of pro-urokinase (uPA) or tissue plasminogen activator (tPA) and plasminogen with melanotransferrin (p97) for a time sufficient to effect regulation thereof.
REFERENCES:
patent: 6455494 (2002-09-01), Jefferies et al.
patent: 2002/0119095 (2002-08-01), Gabathuler et al.
Freshney, R.I. Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc. 1983, New York, p. 4.
Dermer, G.B. Another anniversary for the war on cancer. Bio/technology, 1994. vol. 12, p. 320.
MSNBC News Services, Nov. 9, 2000. Mixed results on new cancer drug.
Gura, T. Systems for identifying new drugs are often faulty. Science, 1997. vol. 278, pp. 1041-1042.
Sala, Roberta et al., European Journal of Cell Biology, vol. 81, No. 11, Nov. 2002, pp. 599-607.
Demeule, Michel et al., Blood, vol. 102, No. 5, Sep. 1, 2003, pp. 1723-1731.
Rose, T.M. et al., Proceedings of the National Academy of Sciences of USA, National Academy of Science. vol. 83, Mar. 1986, pp. 1261-1265.
Schlingemann, R.O. et al., American Journal of Pathology, vol. 136, No. 6, 1990, pp. 1393-1406.
Alemany et al., 1993, J Cell Sci, 104:1155-1162.
Andreasen et al., 1997, Int. J Cancer, 72:1-22.
Baker et al., 1992, FEBS Letters, 298(2,3):215-218.
Bass et al., 2002, J Biol Chem, 277(49):46845-46848.
Brown et al., 1981, Proc Natl Acad Sci USA, 78(1):539-543.
Brown et al., 1982, Nature, 296:171-173.
Bu et al., 1996, J Biol Chem, 271(36):22218-22224.
Conese et al., 1995, J Cell Biol, 131(6):1609-1622.
Cubellis et al., 1989, Proc Natl Acad Sci USA, 86:4828-4832.
Dano et al., 1985, Adv Cancer Res, 44:139-266.
Dehouck et al., 1992, J Neurochem, 58 (5):1790-1797.
Demeule, et al., 2002 J Neurochem 83:924-933.
Fillebeen et al., 1999 J Biol Chem 274(11):7011-7017.
Food et al., 1994 J Biol Chem. 269(4):3034-3040.
Gong et al., 2001 J Biol Chem 276(22):19078-19083.
Herz et al., 2001J Clin Invest 108(6):779-784.
Jefferies et al., 1996 Brain Res 712:122-126.
Johnsson et al., 1991 Anal Biochem 198:268-277.
Kennard et al., 1996 Nat Med 2:1230-1235.
Kozyraki et al., 2001 Proc Natl Acad Sci USA 98(22):12491-12496.
Li et al., 2002 J Biol Chem 277(44):42366-42371.
Liu et al., 2002 J. Biol Chem 276(31):28889-28896.
Min et al., 1996 Cancer Res 56:2428-2433.
Neels et al., 1999 J Biol Chem 274(44):31305-31311.
Nielsen et al., 1988 J. Biol Chem 263(5):2358-2363.
Nykjaer et al., 1997 EMBO J 16(10):2610-2620.
Olson et al., 1992 J Biol Chem 267(13):9129-9133.
Ploug et al., 1991 J Biol Chem 266(3):1926-1933.
Reijerkerk et al., 2000 Eur J Cancer, 36:1695-1705.
Richardson, 2000 Eur J. Biochem 267:1290-1298.
Sekyere et al., 2000 FEBS Letters 483:11-16.
Stahl et al., 1997 Int J Cancer 71:116-122.
Tarui et al., 2002 J Biol Chem 277(37):33564-33570.
Weaver et al., 1997 J Biol Chem 272(22):14372-14379.
Woodbury et al., 1980 Proc Natl Acad Sci USA 77(4):2183-2187.
Woodbury et al., 1981, Int J Cancer, 27:145-149.
Richardson, et al., “The role of the membrane-bound tumour antigent, melanotransferrin (p97), in iron uptake by the human malignant melanoma cell,” Eur.J.Biochem., vol. 267, pp. 1290-1298 (2000).
Sekyere, et al., “Examination of the distribution of the transferrin homologue, melanotransferrin (tumour antigen p97), in mouse and human,” Biochimica, vol. 1722, pp. 131-142 (2005).
Dunn, et al., “The function of melanotransferrin: a role in melanoma cell proliferation and tumorigenesis,” Carcinogenesis, vol. 27, No. 11, pp. 2157-2169 (2006).
Rahmanto, et al., “Identification of distinct changes in gene expression after modulation of melanoma tumor antigen p97 (melanotransferrin) in multiple models in vitro and in vivo,” Carcinogenesis, vol. 28, No. 10, pp. 2172-2183 (2007).
Sekyere, et al., “Role of melanotransferrin in iron metabolism: studies using targeted gene disruption in vivo,” Blood, vol. 107, pp. 2599-2601 (2006).
Beliveau Richard
Bertrand Yanick
Demeule Michel
Jodoin Julie
Michaud-Levesque Jonathan
Birch & Stewart Kolasch & Birch, LLP
Gussow Anne M.
Transfert Plus
LandOfFree
Compound and method for regulating plasminogen activation... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compound and method for regulating plasminogen activation..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compound and method for regulating plasminogen activation... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2721579